Medunik USA confirms continued supply of Pheburane for UCD patients

Medunik USA, a division of the Duchesnay Pharmaceutical Group, confirmed the ongoing availability of Pheburane (sodium phenylbutyrate) for patients diagnosed with urea cycle disorders (UCD). The announcement addresses the current treatment landscape for the rare genetic condition, which requires lifelong management to prevent the accumulation of ammonia in the blood.

Pheburane is an orphan drug designed to assist in the management of UCDs by providing a pharmaceutical option for nitrogen disposal. As the specialty pharmaceutical market for rare diseases shifts, the company aims to maintain access to this therapeutic option for patients requiring consistent treatment protocols.

Urea cycle disorders affect the body's ability to process nitrogen, necessitating specialized long-term care. Medunik USA continues to position its orphan drug portfolio within the U.S. market, focusing on patient accessibility for rare condition treatments.